[go: up one dir, main page]

BRPI0416190A - combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro - Google Patents

combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro

Info

Publication number
BRPI0416190A
BRPI0416190A BRPI0416190-4A BRPI0416190A BRPI0416190A BR PI0416190 A BRPI0416190 A BR PI0416190A BR PI0416190 A BRPI0416190 A BR PI0416190A BR PI0416190 A BRPI0416190 A BR PI0416190A
Authority
BR
Brazil
Prior art keywords
cancer treatment
erbb antibody
antibody combinations
erbb2 inhibitor
selective erbb2
Prior art date
Application number
BRPI0416190-4A
Other languages
English (en)
Inventor
Jitesh Pranlal Jani
Richard Damian Connell
Louis Jean Denis
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0416190A publication Critical patent/BRPI0416190A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçõES SELECTIVAS DE INIBIDOR ERBB2/ANTICORPO ANTI-ERBB NO TRATAMENTO DO CANCRO". Esta invenção relaciona-se com um método de tratamento do cancro com uma combinação de um ligando erbB2 e um anticorpo, em mamíferos. Mais particularmente, esta invenção relaciona-se com um método para tratar o cancro pela administração de um ligando erbB2 em combinação com um anticorpo erbB. Esta invenção também se relaciona com um conjunto de componentes útil no tratamento do crescimento celular anormal em mamíferos, especialmente humanos.
BRPI0416190-4A 2003-11-06 2004-10-27 combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro BRPI0416190A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51763603P 2003-11-06 2003-11-06
US54960004P 2004-03-03 2004-03-03
PCT/IB2004/003551 WO2005044302A1 (en) 2003-11-06 2004-10-27 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0416190A true BRPI0416190A (pt) 2007-01-23

Family

ID=34576806

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416190-4A BRPI0416190A (pt) 2003-11-06 2004-10-27 combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro

Country Status (9)

Country Link
US (1) US20050101618A1 (pt)
EP (1) EP1682176A1 (pt)
JP (1) JP2007510708A (pt)
AR (1) AR046926A1 (pt)
BR (1) BRPI0416190A (pt)
CA (1) CA2544863A1 (pt)
MX (1) MXPA06005024A (pt)
TW (1) TW200518755A (pt)
WO (1) WO2005044302A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN101141981A (zh) * 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
WO2006129168A2 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Bicyclic derivatives for the treatment of abnormal cell growth
ATE507224T1 (de) * 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
JP5465241B2 (ja) 2008-05-29 2014-04-09 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ｈｔ３受容体調節物質ならびにその作製方法および使用
EP2352851A1 (en) 2008-11-12 2011-08-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Use of erbb4 as a prognostic and therapeutic marker for melanoma
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN104093743B (zh) 2011-11-23 2018-04-24 医学免疫有限责任公司 特异于her3的结合分子及其用途
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN107778288B (zh) * 2016-08-26 2020-07-28 正大天晴药业集团股份有限公司 一种喹啉衍生物的杂质及其制备方法和用途
CN107778290B (zh) * 2016-08-30 2020-07-24 正大天晴药业集团股份有限公司 一种喹啉衍生物的杂质及其制备方法
JP7626774B2 (ja) 2020-02-03 2025-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
WO2021156178A1 (en) 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
JP2025510926A (ja) * 2022-04-05 2025-04-15 ボロノイ インコーポレイテッド ヘテロアリール誘導体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US198277A (en) * 1877-12-18 Improvement in means for removing and destroying sewer-gases
US3082831A (en) * 1960-03-23 1963-03-26 Wash Overshot And Spear Engine Combined wash-over and well tubing retriever apparatus
DE60108754T2 (de) * 2000-06-22 2005-06-23 Pfizer Products Inc., Groton Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
MXPA06005024A (es) 2006-07-06
TW200518755A (en) 2005-06-16
CA2544863A1 (en) 2005-05-19
EP1682176A1 (en) 2006-07-26
WO2005044302A1 (en) 2005-05-19
AR046926A1 (es) 2006-01-04
US20050101618A1 (en) 2005-05-12
JP2007510708A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
BRPI0416190A (pt) combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
BR0214499A (pt) Derivados de quinazolina para o tratamento do crescimento anormal das células
DE60329990D1 (de) Mitotische kinesin-hemmer
ECSP066362A (es) Inhibidores de quinesina mitótica.
DE60329756D1 (de) Mitotische kinesin-hemmer
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
WO2005044807A3 (en) Benzoimidazole compounds
MXPA04000222A (es) Combinaciones para el tratamiento de desordenes inflamatorios.
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
EP2425850A3 (en) Bispecific single chain FV antibody molecules and methods of use thereof
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
UA89226C2 (en) Imidazole compounds
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
UA88869C2 (ru) Соединения для нормализации цикла сон/бессонница
BRPI0417674A (pt) método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
TW200507840A (en) Method of treating multiple myeloma
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
SI1684770T1 (sl) Oligo-beta-(1,3)-glukan in monoklonska protitelesa proti raku

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.